Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized double-blind placebo-controlled study of TLL-018 in adults with moderate-to-severe atopic dermatitis
CTR20263146Phase 3Active
- Sponsor
- Highlight Therapeutics
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of girocitinib in atopic dermatitis (AD), sponsored by Highlight Therapeutics. Started Aug 2026; status: active.
02
Drugs
girocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20263146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263146.